GENERICally Speaking Hatch Waxman Bulletin

The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.

GENERICally Speaking Winter 2021

Winter 2021

The Winter 2021 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.

A few of the relevant court decisions highlighted in this issue:

  • Eli Lilly & Co. v. Apotex, Inc.
    Alimta® (pemetrexed disodium)
    The Federal Circuit affirmed the district court’s finding that plaintiff’s amendment to replace “ALIMTA” with “pemetrexed disodium” was not a narrowing amendment.
  • Bracco Diagnostics Inc. v. Maia Pharms., Inc.
    Kinevac® (sincalide)
    The Federal Circuit affirmed the district court’s judgment based on the parties’ stipulation of infringement that resulted from the the district court’s claim construction.
  • Par Pharm., Inc. v. Hospira, Inc.
    Adrenalin® (epinephrine injection)
    The Federal Circuit affirms the trial court’s finding infringement.

Relevant ANDA Updates highlighted in this issue:

Oren D. Langer


Managing Partner, New York Office
Member of Executive Board

Reported settlements in federal district court cases
Federal district court cases that are filed pursuant to the Hatch-Waxman Act

GENERICally Speaking Spring 2021

Spring 2021

GENERICally Speaking Summer 2021

Summer 2021

GENERICally Speaking Fall 2021

Fall 2021